作者: Shuang Zheng , David J. Hunter , Jianhua Xu , Changhai Ding
DOI: 10.1080/14712598.2016.1229774
关键词: Medicine 、 Inflammation 、 Joint disease 、 ADAMTS 、 Bioinformatics 、 Osteoarthritis 、 Pathological 、 Cochrane Library 、 Growth factor 、 Immunology 、 Monoclonal antibody
摘要: ABSTRACTIntroduction: Osteoarthritis (OA) is a multifactorial chronic joint disease, and so far, there are no approved disease-modifying anti-OA drugs (DMOADs). There an urgent need to develop therapies for different phenotypes of OA. Monoclonal antibodies (mAb) may slow structural progression, control inflammation relieve pain, thus have the potential be DMOADs.Areas covered: In this review, authors searched literature on PubMed, EMBASE Cochrane Library using keywords, including mAbs, biological agents, OA osteoarthritis, electronically up May 2016. They also included abstracts international conferences. Furthermore, they reviewed experimental clinical studies various mAbs targeting pathological mechanisms OA, ADAMTS, Interleukine-1, tumour necrosis factor, never growth factor vascular endothelial factor.Expert opinion: MAbs treatment under intense investigation results some (e.g., anti-ner...